ResMed Director Increases Stake with stock Award
Sydney, Australia - ResMed Inc. (AU:RMD) Director Christopher DelOrefice recently acquired 1,073 shares of the company’s common stock thru Restricted Stock Units (RSUs). The shares vest either by November 2026 or at the next annual stockholders’ meeting, according to a recent disclosure.
This transaction signals a continued alignment of leadership interests with those of ResMed shareholders. RSUs are a form of compensation frequently enough used to incentivize executives and directors,tying their financial success to the company’s performance.
ResMed Inc. is a global leader in the healthcare industry, specializing in the growth and manufacturing of devices and cloud-connected solutions for the treatment of sleep disorders, including sleep apnea, and other respiratory conditions.
As of today, AU:RMD maintains a “Buy” rating from analysts with a price target of A$42.00.The company’s current market capitalization is A$56.69B, with an average trading volume of 1,214,271 shares.
Investors can find further analysis of ResMed Inc. CHESS Depositary interests on a ratio of 10 CDIs per ord.sh at https://www.tipranks.com/stocks/au:rmd.
